title: Monitoring of allograft recipients for the development of HLA-specific antibodies: elimination of OKT3 as a complicating factor.
abstract: In this report we demonstrate that the use of immunoabsorbent beads to remove the OKT3 monoclonal antibody (MoAb) from the sera of transplant recipients is necessary in order to avoid the false positive reactivity in panel reactive antibody (PRA) assay. We have shown that the presence of OKT3 MoAb in patient's sera can give a positive reactivity in PRA, which may be interpreted as antibody development. Rabbit antimouse immunoglobulin covalently linked to sepharose can effectively remove the OKT3 MoAb from patients sera, but has no effect on anti-HLA antibodies. The absorbance of OKT3 MoAb, therefore, is necessary to obtain accurate results in respect to humoral rejection, which may lead to mismanagement of patients.
authors.affiliation: Department of Pathology, Baylor University Medical Center, Dallas, Texas, USA.
authors.forename: D
authors.initials: D
authors.lastname: Mulligan
authors.forename: L
authors.initials: L
authors.lastname: Gentry
authors.forename: L
authors.initials: L
authors.lastname: Dombrausky
authors.forename: G
authors.initials: G
authors.lastname: Klintmalm
authors.forename: A
authors.initials: A
authors.lastname: Nikaein
mesh_terms: D000917:Antibody Formation; D003601:Cytotoxicity Tests, Immunologic; D005189:False Positive Reactions; D006084:Graft Rejection / Q000175:diagnosis*; D006680:HLA Antigens / Q000276:immunology*; D006801:Humans; D007163:Immunosorbent Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D016031:Liver Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000008:administration & dosage / Q000097:blood*
chemical_list: D006680:HLA Antigens; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3